tbuckley/cabot-search huggingface dataset:
Comprehensive Mechanism Analysis of Mesoporous‐Silica‐Nanoparticle‐Induced Cancer Immunotherapy
Authors: Xiupeng Wang, Xia Li, Kazuko Yoshiyuki, Yohei Watanabe, Yu Sogo, Tadao Ohno, Noriko M. Tsuji, Atsuo Ito
Journal: Advanced Healthcare Materials (2016)

A plain mesoporous silica nanoparticle without any immunomodulatory molecules significantly enhances anticancer immunity in vivo. Comprehensive mechanism of mesoporous‐silica‐nanoparticle‐induced cancer immunotherapy is analyzed in this paper. The mesoporous silica nanoparticle promotes both Th1 and Th2 immune responses, as it accelerates lymphocytes proliferation, stimulates IFN‐γ, IL‐2, IL‐4, and IL‐10 cytokine secretion by lymphocytes ex vivo, and increases IgG, IgG1, IgG2a, IgM, and IgA antibody titers in mice serum compared with those of alum and adjuvant‐free groups. Moreover, the mesoporous silica nanoparticle enhances effector memory CD4 + and CD8 + T cell populations in three most important immune organs (bone marrow, lymph node, and spleen) of mice compared with those of alum and adjuvant‐free groups three months after adjuvant injection. The present study paves the way for the application of mesoporous silica nanoparticle as immunoadjuvant for cancer immunotherapy.
Abstract 12280: Bispecific Anti-GPIIb/IIIa Single Chain Antibodies for Stem Cell Homing
Authors: Ingo Ahrens, Christoph E Hagemeyer, Franco Klingberg, Ephraem Leitner, Kati Viitaniemi, Fu Jia, Nicole Bassler, Christoph Bode, Karlheinz Peter
Journal: Circulation (2010)

Stem cell therapy has been studied and applied in various clinical fields, including that of myocardial repair and atherosclerosis. However, the efficiency of regenerative cell delivery to areas of...
A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey Study).
Authors: Carmel Maree Jacobs, Iryna Kuchuk, Stephanie Smith, Sasha Mazzarello, Lisa Vandermeer, Nathan Bouganim, Susan Dent, Stan Z. Gertler, Shailendra Verma, Vince Young, Xinni Song, Demetrios Simos, George Dranitsaris, David Cella, Mark Clemons
Journal: Journal of Clinical Oncology (2014)

155 Background: Questions remain around the optimal use of bone-targeted agents (BTA) in patients with bone metastases (BM) from breast cancer (BC). In Canada pamidronate (PAM) is the most commonly used BTA in BC.We explored whether a switch to a more potent BTA, like zoledronic acid (ZA), in patients who remain at high risk of skeletal related events (SREs) despite PAM use is associated with significant palliative benefit. Methods: BC patients with high risk BM (prior SRE, bone progression, bone pain or levels of bone turnover marker serum C-telopeptide (sCTX) &gt;400ng/L) despite &gt;3 months of PAM use were eligible. Patients were randomized in a double–blind manner to either switch to ZA or continue on PAM every 4 weeks for 12 weeks. Primary outcome was the proportion of patients achieving a fall in sCTX at 12 weeks. Secondary outcomes were pain control (BPI and FACT-BP) and toxicity. Results 73 patients completed the study. Median age 61 years (range 37 – 87), prior duration of PAM use 10 months (range 3 – 118). sCTX levels for all patients at baseline, 372+/- 471, week 12, 209 +/-290. Proportion of patients achieving a fall in sCTX from week 0 to week 12, 26/31 (84%) in ZA arm, 17/30 (57%) in PA arm, p=0.0262. Two patients were unable to complete the study due to deterioration in renal function (both receiving PAM), four due to progressive disease (two receiving ZA, two PAM), two patients chose to discontinue the study before completion (both receiving ZA). Four patients (5%) had SRE’s during the study, two receiving ZA, two receiving PAM. Quality of life and pain analysis shows no difference between week 0 and week 12 scores in either arm. Toxicity was predominantly grade 1 and 2, numerically there were more adverse effects in the ZA arm than PAM. Conclusion Switching patients with high risk BM from PAM to ZA leads to a reduction in sCTX levels but may be associated with more toxicity. Quality of life and pain scores were similar between the two treatments. While the literature suggests that a reduction in sCTX may correlate with reduced rate of SREs, given the lack of symptom improvement a switching strategy cannot be recommended. NCT01907880 Clinical trial information: NCT01907880.
Biological effects of oral nanoporous carbon in bile duct ligated rats
Authors: Jane Macnaughtan, J. Soeda, A. Mouralidarane, Susan Sandeman, Carol Howell, O.P. Kozynchenko, S.R. Tennison, Sergey Mikhalovsky, N. Davies, J. Oben, R. Mookerjee, Rajiv Jalan
Journal: Gut (2012)
The effect of antisense oligodeoxynucleotides targeting Aurora A kinase on cell proliferation and chemosensitivity to paclitaxel in human lung cancer cell line A549
Authors: R. Meng, G. Wu, K. Y. Yang, J. Cheng
Journal: Journal of Clinical Oncology (2007)

21147 Background: Aurora kinases representing a family of evolutionarily conserved mitotic serine/threonine kinases have been found elevated in lung andenocarcinoma cell line A549. It is suggested that the overexpression of Aurora A contributes to the carcinogenesis, chromosomal instability (CIN), and de-differentiation of lung cancers. To address its possibility as a therapeutic target for lung cancer, we employed the antisense oligodeoxynucleotide (ASODN) technique to inhibit Aurora A expression and investegate its effect on tumor growth and cell cycle of A549, as well as the chemosensitivity of paclitaxel. Methods: Aurora A ASODN was synthesized and transfected into A549 cells by lipofectAMINE 2000.Aurora A mRNA and protein expression were examined by reverse transcription -polymerase chain reaction (RT-PCR) and Western blot respectively.Cell cycle distribution was observed by flow cytometer.MTT assay was used to evaluate cell inhibition ratio before and after transfection. Results: The proliferation of the A549 cells was inhibited by Aurora A ASODN dose and time dependently. It was also observed that the IC 50 of A549 cells after 48 hours’ treatment of ASODN was about 300nmol/L and under such circumstances, the Aurora A mRNA and protein expression significantly decreased (P&lt;0.05), along with the induction of accumulation of cells in S phase and the G2-M transition. Furhermore, cell inhibition ratio of the combination of Aurora A ASODN and paclitaxel was higher significantly than paclitaxel(P&lt;0.05) or Aurora A ASODN alone (P&lt;0.05). Conclusions: Inhibition of Aurora A expression can results in the suppression of cell growth and chemosensitizing activity to paclitaxel in human lung cancer cell line A549. No significant financial relationships to disclose.
Thymomas and Thymic Hyperplasia in &lt;italic&gt;Praomys (Mastomys) natalensis&lt;/italic&gt;. Concomitant Myositis, Myocarditis, and Sialodacryoadenitis
Authors: Harold L. Stewart, Katharine C. Snell
Journal: JNCI Journal of the National Cancer Institute (1968)

Twenty-seven thymomas and 11 hyperplastic thymuses were observed in a series of 113 untreated Mastomys from which histologic sections of the thymus were available for examination. Most of the Mastomys with thymic lesions were over 2 years old, and two-thirds of them were females. The histologic pattern of the thymomas corresponded closely with that of the thymomas in man in which the normal relationship of cortex to medulla is effaced and the different thymic cellular and structural components appear in abnormal relationships to each other. In the hyperplastic thymuses, the pattern of cortical and medullary markings was reproduced, although lacking somewhat the regularity seen in the noninvoluted thymus of young animals. Myositis and atrophy of skeletal muscle were present in one Mastomys with thymic hyperplasia and in 7 with thymomas. Nearly one-third of the animals with thymomas had severe myocarditis, and over two-thirds had chronic inflammation often associated with degeneration and atrophy of the extraorbital and intraorbital lacrimal, lingual, harderian, or one or more of the salivary glands. These lesions were noted, but less frequently, in the Mastomys with hyperplasia of the thymus. The possibility is considered that the thymomas, thymic hyperplasia, myositis, myocarditis, and other inflammatory lesions might have some relationship to myasthenia gravis or other diseases of man believed by some to be associated with autoimmunity. Many of the 38 Mastomys with hyperplasia of the thymus or thymoma also had neoplasms of other organs, but these were estimated to be no more frequent than in our entire colony.
Mammalian Chromosomes &lt;italic&gt;In Vitro&lt;/italic&gt;. XIX. Chromosomes of Don-C, a Chinese Hamster Fibroblast Strain With a Part of Autosome 1b Translocated to the Y Chromosome&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Elton Stubblefield
Journal: JNCI Journal of the National Cancer Institute (1966)

Don-C is a cloned strain of the diploid male cell line Don of the Chinese hamster. The chromosomes of this cell strain were analyzed with respect to karyotype, replication pattern, and segmentation pattern. The results indicated that the distal third of the short arm of autosome 1b had been translocated to the Y chromosome. The replication pattern of the autosomal segment in its new position appeared to be unchanged. The relevance of this observation to the theory of Lyon is discussed.
Potential Barriers to the Diffusion of Surgical Innovation
Authors: Faiz Gani, Daniel E. Ford, Timothy M. Pawlik
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study
Authors: Matthew R Moore, Ruth Link-Gelles, William Schaffner, Ruth Lynfield, Corinne Holtzman, Lee H Harrison, Shelley M Zansky, Jennifer B Rosen, Arthur Reingold, Karen Scherzinger, Ann Thomas, Ramon E Guevara, Tasneem Motala, Jeffrey Eason, Meghan Barnes, Susan Petit, Monica M Farley, Lesley McGee, James H Jorgensen, Cynthia G Whitney
Journal: The Lancet Respiratory Medicine (2016)
Pharmacodynamically guided dose selection of PF-00337210, a VEGFR2 tyrosine kinase (TK) inhibitor, in a phase I study.
Authors: G. Liu, P. LoRusso, E. I. Heath, J. Y. Bruce, A. M. Traynor, M. Pilat, A. Breazna, M. Tortorici, D. R. Shalinsky, A. D. Ricart
Journal: Journal of Clinical Oncology (2010)

3033 Background: PF-00337210 is a highly potent and selective ATP-competitive inhibitor of VEGFR2 TK with a cellular IC50 of 0.8 nM. In vivo, it inhibits tumor angiogenesis and human xenograft growth. Modulation of blood pressure (BP) and vascular permeability (volume transfer constant: Ktrans) appear to be suitable markers of efficacy for VEGF/VEGFR inhibitors. Methods: Safety, MTD, and recommended phase 2 dose of PF-00337210 were assessed. Pharmacokinetics (PK) and pharmacodynamics (PD) were also evaluated, including acute effects on Ktrans by DCE-MRI (day 2 compared with baseline) and weekly BP measurements. The study had a strict normotensive eligibility criterion as documented by 3 screening BP readings ≤140/85 mmHg over 3 days without any antihypertensive medication (AHM). Results: 46 patients (pts) with advanced solid tumors were treated with PF- 00337210 (30 at doses of 0.67–9 mg QD, 4 at 4 mg BID, and 12 at 6 mg BID). 19 pts (41%) previously received VEGF/VEGFR inhibitors. The MTD with the QD schedule is 8 mg. There was only one DLT (G3 hand–foot syndrome) with BID dosing, but further dose escalation ceased secondary to significant PD findings. Common drug-related adverse events were hypertension (HTN), proteinuria, fatigue, diarrhea, and nausea. HTN incidence and intensity corresponded with dose, but was well controlled with AHM (diastolic BP was >90 mmHg at least once during treatment in 33% and 81% of pts on QD and BID dosing respectively). Exposures (AUC0–24) were generally linear and variability ranged from 23 to 41% at BID doses. PK data indicated that mean (%CV) AUC0–24 at 6 mg BID (n=6) was 456 ng·h/mL (25) at steady-state. Median drug exposure was higher for pts who had diastolic BP >90 mmHg vs. those who did not. A hierarchical mixed-effect model analysis of Ktrans showed 14 vascular responders of 19 pts with complete MRI scans. One partial response was confirmed and 6 pts had stable disease ≥4 months in BID cohorts. Conclusions: PF-00337210 is well tolerated at 6 mg BID, with profound VEGFR inhibition effects (as measured by elevated BP and a significant decrease in tumor vascular parameters by DCE-MRI). Biomarkers assisted in the dose and schedule selection of PF-00337210. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer Pfizer Pfizer Pfizer
Clinical response rate at primary tumor site by WHO criteria following an induction chemotherapy regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC).
Authors: D. I. Kuperman, J. Ley, B. Nussenbaum, H. Gay, W. L. Thorstad, T. Rachocki, J. Subramanian, D. Adkins
Journal: Journal of Clinical Oncology (2010)

e16028 Background: Achievement of a complete (CR) or partial (PR) response at the primary tumor site to induction chemotherapy (IC) with cisplatin and 5-FU correlates with disease control after subsequent definitive radiation-based therapy (RT) in patients with HNSCC. T stage is the primary determinant of tumor response to IC. The likelihood of CR/PR after IC is high in T1/2 tumors and low in T3/4 tumors. SPARC, an albumin binding protein that is commonly overexpressed in HNSCC, may facilitate preferential accumulation of nab- paclitaxel at tumor sites compared to other formulations of paclitaxel. Methods: Primary objectives of this prospective phase II trial were to determine the clinical CR and PR rate at the primary tumor site to an IC regimen of weekly nab-paclitaxel (100 mg/m2) and cetuximab (250 mg/m2) with every 3 week cisplatin (75 mg/m2) and 5-FU (750 mg/m2 per day ×3 CIVI) (ACCF) given for two cycles (over 6 weeks) in patients with locally advanced nonmetastatic HNSCC. The assessment of primary tumor response was performed by the treating physician by clinical examination using WHO criteria. Size (cm2) of the primary tumor was based on bi- dimensional measurements. Results: To date, 10 patients were enrolled. T stage breakdown were: T4 (5 patients), T3 (4 patients), and T2 (1 patient). All 10 patients completed the ACCF portion of the trial and subsequently received definitive chemotherapy and radiation. Three of the 10 patients had CR at the primary site (see Table). The remaining 7 patients had PR at the primary site, all with ≥ 75% reduction in size of the primary tumor. Conclusions: The early results of this trial suggest that ACCF is an effective, novel IC regimen that resulted in a high likelihood of a favorable (CR/PR) tumor response at the primary site in patients with high T stage HNSCC. Patient 1 2 3 4 5 6 7 8 9 10 T stage T3 T2 T4 T3 T3 T4 T4 T4 T3 T4 % response (↓in cm2) to IC regimen at primary site 100% >75% 100% 75% 95% 85% 95% 100% 75% 80% Response at primary tumor site by WHO CR PR CR PR PR PR PR CR PR PR No significant financial relationships to disclose.
Differences between midlife female offenders and those younger than 40
Authors: A E Daniel, P W Harris, S A Husain
Journal: American Journal of Psychiatry (1981)

The authors studied 66 women referred for forensic evaluation and classified them into two age groups: 48 women 17-39 years old composed a young adult group and 18 women 40-54 years old composed a midlife group. The midlife group included a significantly larger number of first-time offenders with a higher frequency of medical as well as psychiatric disorders. None of the women in the midlife group was diagnosed as having antisocial personality disorder, but this was the most common diagnosis among the younger women. The authors note the implications of these findings for treatment of older female offenders, especially those in midlife.
Observations on the Nature of a Genetic Cellular Resistance to Avian Tumor Viruses&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Lyman B. Crittenden
Journal: JNCI Journal of the National Cancer Institute (1968)

The subgroup A pseudotype of the Bryan high-titer strain of Rous sarcoma virus [RSV (RAV-1)] and chick embryo fibroblasts resistant to subgroup A (C/A and C/AB) were chosen for study. Attempts to infect resistant cells with free virus showed that resistance was very efficient, if not absolute. Resistant cells removed virus from the medium as efficiently as susceptible cells, which indicated that genetic cellular resistance did not affect adsorption. However, both C/A and C/AB cells synthesized RSV (RAV-1) after growth in contact with lethally irradiated RSV (RAV-1)-producing susceptible cells. Therefore, the genetically controlled block apparently occurred at the level of penetration or uncoating, but did not affect the cell's ability to synthesize the excluded virus, provided the viral genome had entered. The mechanism of penetration of the viral genome into resistant cells during cocultivation with irradiated virus-producing cells is not clear. Possible mechanisms are discussed.
Clinical characteristics and outcomes of <i>BRCA</i>-associated ovarian cancer (OC): Genotype and survival.
Authors: V. Engelstaedter, M. C. Cristea, J. E. Garber, S. L. Neuhausen, P. H. Frankel, S. Sand, L. Steele, U. Matulonis, J. Liu, J. Weitzel
Journal: Journal of Clinical Oncology (2010)

5017 Background: Mutations in BRCA1 and BRCA2, tumor-suppressor genes with distinct roles in homologous recombination repair, are associated with an increased risk of OC. Prior studies have suggested that BRCA carriers with OC have an improved survival compared to sporadic OC. However, few studies have examined whether clinical features and survival of OC differs between BRCA1- and BRCA2-deficient tumors. We compared clinical features and outcome by genotype of a cohort of women with BRCA-associated OC. Methods: Clinical data, including age, stage, and BRCA genotype were obtained and treatment history abstracted from chart review of patient records for BRCA-associated OC cases identified through retrospective review of participants in IRB-approved registry studies at 3 cancer centers. Clinical characteristics, event-free (EFS) and overall survival (OS) for BRCA1 vs. BRCA2 mutation were examined in multivariate analyses. Results: 164 cases were identified (119 BRCA1; 45 BRCA2). BRCA2 patients had a higher mean age (56.7 vs. 52.2 years; p < 0.01), and fewer poorly differentiated tumors (69% vs. 87%; p < 0.02), with no significant difference in the proportion with advanced stage (3 or 4) (85/118 [72%] for BRCA1 and 31/45 [69%] for BRCA2). No significant difference in EFS was observed. However, OS at 5-years was 73% (95% CI 60-89) for BRCA2 and 63% (95% CI 54-73) for BRCA1. In multivariate analysis, adjusting for age and stage, BRCA2 carriers had a nonsignificant reduced risk of death (HR = 0.6, 95% CI 0.31-1.14, p = 0.12) compared to BRCA1 carriers. In patients with advanced stage (> 3A), BRCA2 was associated with a significantly reduced risk of death (HR = 0.45, 95% CI 0.21-0.98, p < 0.05, adjusted for age). Conclusions: While women with BRCA-associated OC have better survival than those with sporadic disease, this is the largest set of BRCA-associated OC cases to date indicating that BRCA2 may be associated with better survival than BRCA1. This may reflect important differences between genotypes in tumor characteristics including chemotherapy sensitivity, or a greater tendency of particular mutations towards developing platinum-resistance. No significant financial relationships to disclose.
Henna—A Temporary Body of Art
Authors: Mindy X. Wang, Eric L. Maranda, Jacqueline Cortizo, Victoria Lim, Joaquin Jimenez
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal